Article
Oncology
Giovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J. Klempner, Steven B. Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano Salati, Akihito Kawazoe, Valerie Zhu, Darren Cowzer, Virginia Genovesi, Sara Lonardi, Kohei Shitara, Thierry Andre, Filippo Pietrantonio
Summary: This study found that immune checkpoint inhibitor-based therapy is superior to chemotherapy in patients with dMMR and/or MSI-high advanced gastric or gastroesophageal junction adenocarcinoma. However, more studies are needed to examine prognostic features within this patient population.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Woorim Kim, Young-Ah Cho, Dong-Chul Kim, A-Ra Jo, Kyung-Hyun Min, Kyung-Eun Lee
Summary: This study aims to investigate factors associated with thyroid dysfunction in cancer patients receiving PD-1/PD-L1 inhibitors and develop machine learning approaches to predict complications. The results showed smoking history, hypertension, and opioids are associated with thyroid-related adverse events. Machine learning models, particularly random forest, demonstrated good predictive performance for such events.
Article
Oncology
Chian-Wei Chen, Chien-Yu Lin, Jeng-Shiuan Tsai, Chia-Yin Lin, Chao-Chun Chang, Yi-Ting Yen, Yau-Lin Tseng, Po-Lan Su, Chien-Chung Lin
Summary: Combination therapy with chemotherapy and immune checkpoint inhibitors (ICIs) has been shown to improve overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). However, there is a higher incidence of adverse events and treatment discontinuation. We investigate the neutrophil-to-lymphocyte ratio (NLR) as a predictive biomarker, especially in patients with low PD-L1 expression.
FRONTIERS IN ONCOLOGY
(2023)
Letter
Medicine, General & Internal
Alec Zhu, Jorge Alberto Garcia, Bishoy Faltas, Petros Grivas, Pedro Barata, Jonathan E. Shoag
Summary: This cohort study examines the long-term survival of patients with metastatic urothelial carcinoma treated with immune checkpoint inhibitors by analyzing published clinical trial data.
Review
Immunology
Yinan Yu, Xueying Jin, Xiaoling Zhu, Yan Xu, Wei Si, Jianguo Zhao
Summary: Through meta-analysis, the study found that PD-1/PD-L1 immune checkpoint inhibitors combined with chemotherapy can significantly improve the progression-free survival of patients with metastatic triple negative breast cancer, but only significantly improve the overall survival in PD-L1 positive population. In addition, the incidence of immune-related adverse events is significantly higher in the ICIs group compared to chemotherapy, which needs to be taken seriously.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Li Chen, Ruihu Zhao, Hao Sun, Rong Huang, Hongming Pan, Yanjiao Zuo, Lele Zhang, Yingwei Xue, Xingrui Li, Hongjiang Song
Summary: This study aimed to investigate the prognostic value of the gastric immune prognostic index (GIPI) in gastric cancer patients treated with PD-1/PD-L1 inhibitors. The results showed that patients with GIPI intermediate/poor had shorter progression-free survival (PFS) and overall survival (OS) compared to those with GIPI good, especially in subgroups of patients receiving immune checkpoint inhibitor (ICI) treatment and patients with PD-1/PD-L1 positive status. Therefore, GIPI may be useful for identifying gastric cancer patients who are unlikely to benefit from PD-1/PD-L1 inhibitor treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Giacomo Nuvola, Matteo Rosellini, Elisa Tassinari, Javier Molina-Cerrillo, Zin W. Myint, Tomas Buchler, Fernando Sabino Marques Monteiro, Enrique Grande, Matteo Santoni, Francesco Massari
Summary: This meta-analysis confirms that adjuvant PD-1/PD-L1 inhibitors can reduce the risk of relapse in various types of solid tumors. The benefit is consistent across different patient populations, including gender and age subgroups.
Article
Oncology
Antonella Fameli, Valerio Nardone, Mojtaba Shekarkar Azgomi, Giovanna Bianco, Claudia Gandolfo, Bianca Maria Oliva, Marika Monoriti, Rita Emilena Saladino, Antonella Falzea, Caterina Romeo, Natale Daniele Calandruccio, Domenico Azzarello, Rocco Giannicola, Luigi Pirtoli, Antonio Giordano, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Grazia Cusi, Luciano Mutti, Cirino Botta, Pierpaolo Correale
Summary: Peripheral immune-checkpoint blockade with PD-1/PD-L1 antibodies is a promising treatment strategy for mNSCLC patients. This study investigates the impact of PD-1/PD-L1 blockade on specific immune cell subsets and suggests a correlation between immune subpopulation deregulation and autoimmunity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Wen Kou, Yan Yan Lin, Fei Su, Yue Xiang, Hui Qiao, Xin'An Wu, Xiao-Ming Hou
Summary: This study aimed to evaluate the impact of a pharmaceutical care program in reducing adverse events in NSCLC patients receiving ICIC therapies. The program, which involved pharmacist interventions, optimized drug therapy and resulted in significant decreases in adverse events such as nausea, constipation, diarrhea, and myelosuppression.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Jan-Malte Placke, Camille Soun, Jenny Bottek, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pfoehler, Jens Ulrich, Alexander Kreuter, Christiane Pfeiffer, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Michael Weichenthal, Lisa Zimmer, Elisabeth Livingstone, Juergen C. Becker, Georg Lodde, Antje Sucker, Klaus Griewank, Susanne Horn, Eva Hadaschik, Alexander Roesch, Dirk Schadendorf, Daniel Robert Engel, Selma Ugurel
Summary: This study investigated the digitally quantified tumor PD-L1 expression for predicting the outcome of PD-1-based immune checkpoint blockade therapy. Results showed that patients with PD-L1-positive tumors had better response and prolonged progression-free survival and overall survival. Both digital and physician quantification of PD-L1 expression were independent predictors of survival in patients receiving PD-1-based ICB therapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yeon-Hee Baek, Eun Joo Kang, Soojung Hong, Sohee Park, Ju Hwan Kim, Ju-Young Shin
Summary: A study using a nationwide healthcare database in South Korea found that the concomitant use of proton pump inhibitors (PPIs) was associated with a poor prognosis in patients with nonsmall cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICIs). Further prospective studies are needed to determine the risk-benefit balance of using PPIs and ICIs concurrently, particularly in patients with viral hepatitis.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Review
Immunology
Muhammad Khan, Kunpeng Du, Meiling Ai, Baiyao Wang, Jie Lin, Anbang Ren, Chengcong Chen, Zhong Huang, Wenze Qiu, Yawei Yuan, Yunhong Tian
Summary: This study systematically analyzed the biomarker value of PD-L1 expression in predicting the efficacy of PD-1/PD-L1 checkpoint inhibitors in mTNBC patients. The results showed that PD-L1+ patients had significantly higher objective response rate, 1-year progression-free survival, and 2-year overall survival compared to PD-L1- patients. Subgroup analysis indicated that PD-L1 expression can successfully predict tumor response and 2-year overall survival benefit in mTNBC patients regardless of the type of investigating agent, line of treatment administration, and to some extent the type of treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Christine Son, Melissa Y. Y. Moey, Paul R. Walker, Abdul R. Naqash, Matthew Sean Peach, Andrew W. Ju
Summary: In this retrospective study, data was collected on Stage III-IV lung cancer patients who received immune checkpoint inhibitors (ICIs) between 2015 and 2018. The risk of cardiotoxicity was assessed in patients who received thoracic radiotherapy compared to those who did not, and no significant difference was found in the occurrence of cardiotoxicities between the two groups.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Alice Nervo, Matteo Ferrari, Giovanni Gruosso, Enrica Migliore, Sara Basile, Valentina D'Angelo, Anna Roux, Alessandro Piovesan, Emanuela Arvat
Summary: This study retrospectively analyzed the relationship between anti-thyroid peroxidase antibodies (anti-TPO Abs) level and the development of abnormal thyroid function tests (DYSTHYR) during treatment with immune checkpoint inhibitors (ICIs). It found that high baseline anti-TPO Abs level was a risk factor for the onset of DYSTHYR, and DYSTHYR was associated with longer overall survival (OS).
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Oncology
Martin T. King, David D. Yang, Vinayak Muralidhar, Brandon Mahal, Santino Butler, Phillip M. Devlin, Larissa J. Lee, Kent W. Mouw, Neil M. Martin, Anthony V. D'Amico, Paul L. Nguyen, Peter F. Orio
Article
Oncology
Alexander P. Cole, Sean A. Fletcher, Sebastian Berg, Junaid Nabi, Brandon A. Mahal, Guru P. Sonpavde, Paul L. Nguyen, Stuart R. Lipsitz, Maxine Sun, Toni K. Choueiri, Mark A. Preston, Adam S. Kibel, Quoc-Dien Trinh
Article
Oncology
Shuang G. Zhao, William S. Chen, Rajdeep Das, S. Laura Chang, Scott A. Tomlins, Jonathan Chou, David A. Quigley, Ha X. Dang, Travis J. Barnard, Brandon A. Mahal, Ewan A. Gibb, Yang Liu, Elai Davicioni, Linda R. Duska, Edwin M. Posadas, Shruti Jolly, Daniel E. Spratt, Paul L. Nguyen, Christopher A. Maher, Eric J. Small, Felix Y. Feng
CLINICAL CANCER RESEARCH
(2019)
Article
Urology & Nephrology
David D. Yang, Brandon A. Mahal, Vinayak Muralidhar, Neil E. Martin, Peter F. Orio, Kent W. Mouw, Martin T. King, Toni K. Choueiri, Quoc-Dien Trinh, Karen E. Hoffman, Daniel E. Spratt, Felix Y. Feng, Paul L. Nguyen
Letter
Urology & Nephrology
Brandon A. Mahal, Mohammed Alshalalfa, Daniel E. Spratt, Elai Davicioni, Shuang G. Zhao, Felix Y. Feng, Timothy R. Rebbeck, Paul L. Nguyen, Franklin W. Huang
Letter
Medicine, General & Internal
Brandon A. Mahal, Santino Butler, Idalid Franco, Daniel E. Spratt, Timothy R. Rebbeck, Anthony V. D'Amico, Paul L. Nguyen
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2019)
Letter
Oncology
Nina N. Sanford, David J. Sher, Xiaohan Xu, Ayal A. Aizer, Brandon A. Mahal
Article
Oncology
William S. Chen, Mohammed Alshalalfa, Shuang G. Zhao, Yang Liu, Brandon A. Mahal, David A. Quigley, Ting Wei, Elai Davicioni, Timothy R. Rebbeck, Philip W. Kantoff, Christopher A. Maher, Karen E. Knudsen, Eric J. Small, Paul L. Nguyen, Felix Y. Feng
CLINICAL CANCER RESEARCH
(2019)
Review
Oncology
William C. Jackson, Jessica Silva, Holly E. Hartman, Robert T. Dess, Amar U. Kishan, Whitney H. Beeler, Laila A. Gharzai, Elizabeth M. Jaworski, Rohit Mehra, Jason W. D. Hearn, Todd M. Morgan, Simpa S. Salami, Matthew R. Cooperberg, Brandon A. Mahal, Payal D. Soni, Samuel Kaffenberger, Paul L. Nguyen, Neil Desai, Felix Y. Feng, Zachary S. Zumsteg, Daniel E. Spratt
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Letter
Medicine, General & Internal
Brandon A. Mahal, Franklin W. Huang
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2019)
Article
Oncology
Santino S. Butler, Brandon A. Mahal, Nayan Lamba, Matthew Mossanen, Neil E. Martin, Kent W. Mouw, Paul L. Nguyen, Vinayak Muralidhar
Article
Oncology
Amandeep R. Mahal, Santino Butler, Idalid Franco, Vinayak Muralidhar, Dalia Larios, Luke R. G. Pike, Shuang G. Zhao, Nina N. Sanford, Robert T. Dess, Felix Y. Feng, Anthony V. D'Amico, Daniel E. Spratt, James B. Yu, Paul L. Nguyen, Timothy R. Rebbeck, Brandon A. Mahal
Article
Oncology
Stephanie Alimena, David D. Yang, Alexander Melamed, Brandon A. Mahal, Michael J. Worley, Sarah Feldman, Kevin M. Elias, Peter F. Orio, Larissa J. Lee, Martin King
GYNECOLOGIC ONCOLOGY
(2019)
Article
Oncology
Vinayak Muralidhar, Jingbin Zhang, Qiqi Wang, Brandon A. Mahal, Santino S. Butler, Daniel E. Spratt, Elai Davicioni, Oliver Sartor, Felix Y. Feng, Kent W. Mouw, Paul L. Nguyen
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2019)
Letter
Oncology
Nina N. Sanford, Brandon A. Mahal